NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.7023
-0.0166 (-2.31%)
At close: Jul 16, 2026, 4:00 PM EDT
0.7163
+0.0140 (1.99%)
After-hours: Jul 16, 2026, 6:39 PM EDT
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$654,412
Market Cap
24.83M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| IGC Pharma | 70 |
| Evaxion | 46 |
| NextCure | 40 |
| Plus Therapeutics | 28 |
| Barinthus Biotherapeutics | 14 |
| Tvardi Therapeutics | 12 |
| VYNE Therapeutics | 10 |
NRSN News
- 10 days ago - NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - PRNewsWire
- 17 days ago - NeuroSense says Phase 2b PARADIGM study of PrimeC in ALS met endpoint - TheFly
- 17 days ago - NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - PRNewsWire
- 21 days ago - NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease - PRNewsWire
- 24 days ago - EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots - PRNewsWire
- 5 weeks ago - NeuroSense granted South Korean patent covering PrimeC composition for ALS - TheFly
- 5 weeks ago - NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS - PRNewsWire
- 5 weeks ago - NeuroSense granted Japanese patent for PrimeC novel composition in ALS - TheFly